Systemic Sclerosis Associated Interstitial Lung Disease: New Directions in Disease Management

Research output: Contribution to journalReview articlepeer-review

5 Scopus citations

Abstract

A subgroup of patients with systemic sclerosis (SSc) develop interstitial lung disease (ILD), characterized by inflammation and progressive scarring of the lungs that can lead to respiratory failure. Although ILD remains the major cause of death in these individuals, there is no consensus statement regarding the classification and characterization of SSc-related ILD (SSc-ILD). Recent clinical trials address the treatment of SSc-ILD and the results may lead to new disease-altering therapies. In this review, we provide an update to the diagnosis, management and treatment of SSc-ILD.

Original languageEnglish (US)
Article number248
JournalFrontiers in Medicine
Volume6
DOIs
StatePublished - Oct 31 2019

Keywords

  • cyclophosphamide
  • interstitial lung disease
  • nintedanib
  • pirfenidone
  • scleroderma
  • systemic sclerosis

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Systemic Sclerosis Associated Interstitial Lung Disease: New Directions in Disease Management'. Together they form a unique fingerprint.

Cite this